Management ChangeAug 6, 2026, 11:11 AM
STAAR Surgical Appoints Warren Foust as CEO
AI Summary
STAAR Surgical Company announced the appointment of Warren Foust as President and Chief Executive Officer, effective August 4, 2026. Mr. Foust, who previously served as Interim Co-CEO, President & COO, will also join the Board of Directors. Concurrently, Deborah Andrews, former Interim Co-CEO, will continue in an expanded role as Executive Vice President and Chief Financial Officer. Mr. Foust's compensation package includes an annual base salary of $730,000, eligibility for a cash bonus program, and a significant equity component tied to time-vesting and stock price performance hurdles.
Key Highlights
- Warren Foust appointed President and CEO, effective August 4, 2026.
- Mr. Foust also appointed as a new member of the Board of Directors.
- Deborah Andrews appointed Executive Vice President and Chief Financial Officer.
- Mr. Foust's annual base salary set at $730,000.
- Eligible for annual cash bonus program with target 70-100% of base salary.
- Equity compensation includes time-based stock options (20%), time-based RSUs (20%), and performance-based stock options (60%).
- Performance-based options have stock price hurdles of $50, $75, and $100 per share.
- CEO Grant includes 22,493 time-vesting RSUs, 40,471 time-vesting options, and 131,830 performance-vesting options.
Price Impact
More from STAA